Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDEXX LaboratoriesMIL:1IDXX +1.89%78 FCF Margin % is 26.51% as of Jun. 2026, which is 51% above its 10-year median of 17.61. GuruFocus rates MIL:1IDXX with a GF Score™ of 78/100 and a GF Value™ of €520.05 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 95.59% on this metric.
The historical rank and industry rank for IDEXX Laboratories's FCF Margin % or its related term are showing as below:
MIL:1IDXX'
s FCF Margin % Range Over the Past 10 Years
Min: 11.41 Med: 17.61 Max: 27.14
Current: 27.47
During the past 13 years, the highest FCF Margin % of IDEXX Laboratories was 27.14%. The lowest was 11.41%. And the median was 17.61%.
MIL:1IDXX's FCF Margin % is ranked better than 95.59% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.44
vs MIL:1IDXX: 27.47
The historical data trend for IDEXX Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (MIL:1IDXX) has a FCF Margin % of 26.51% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on IDEXX Laboratories and its competitors. This is 51% above median its historical median of 17.61. Over the past decade, IDEXX Laboratories' FCF Margin % has ranged from 11.41 to 27.14. According to the industry distribution chart, IDEXX Laboratories ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 4.4%.
Is IDEXX Laboratories' FCF Margin % too high?
IDEXX Laboratories' current FCF Margin % of 26.51% is 51% above median its 10-year median of 17.61. Over the past 10 years, this metric has ranged from a low of 11.41 to a high of 27.14. The Medical Diagnostics & Research industry median FCF Margin % is 0.44. IDEXX Laboratories' value of 26.51% is 5925% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #9 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' FCF Margin % compare to A and IQV?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #9 out of 204 companies for FCF Margin %. This places IDEXX Laboratories in the top 4% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 0.44. IDEXX Laboratories' value of 26.51% is 5925% above this benchmark. Historically, IDEXX Laboratories' own FCF Margin % has ranged from 11.41 to 27.14 over the past decade. While the company's 10-year median is 17.61 vs. the industry median of 0.44, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
The median FCF Margin % among Medical Diagnostics & Research companies is 0.44, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current FCF Margin % of 26.51% is 5925% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median FCF Margin % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current FCF Margin % is 26.51%, which is 51% above median its own 10-year median of 17.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (MIL:1IDXX) is currently considered Modestly Undervalued. The stock's GF Value™ is €520.05, compared to a current price of €448.40 — trading 13.8% below its estimated fair value. The current FCF Margin % is 26.51%, which is 51% above median its 10-year median of 17.61 and 5925% above the Medical Diagnostics & Research industry median of 0.44. IDEXX Laboratories' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For IDEXX Laboratories (MIL:1IDXX), the current FCF Margin % is 26.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (MIL:1IDXX) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €448.40 is trading 13.8% below its estimated GF Value™ of €520.05.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for MIL:1IDXX:
FCF Margin %: 26.51% (51% above median its 10-year median of 17.61)
GF Value™: €520.05 vs. price of €448.40 (13.8% below fair value)
Industry Position: 5925% above the Medical Diagnostics & Research median (#9 of 204)
No single metric tells the full story. See the MIL:1IDXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
78GF Score
Get the complete analysis for MIL:1IDXX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1IDXX has been successfully added to your 
